Literature DB >> 17496983

Utilizing IL-12, IL-15 and IL-7 as Mucosal Vaccine Adjuvants.

Liljana Stevceva1, Marcin Moniuszko, Maria Grazia Ferrari.   

Abstract

In this paper we review and discuss three of the most exciting and promising cytokines for therapeutic intervention and immunomodulation of immune responses including those on mucosal surfaces. The main properties of IL-12, IL-15 and IL-7 are described and the studies utilizing these cytokines as immunomodulators and vaccine adjuvants discussed.

Entities:  

Year:  2006        PMID： 17496983      PMCID： PMC1868013          DOI： 10.2174/157018006778194655

Source DB:  PubMed          Journal:  Lett Drug Des Discov        ISSN： 1570-1808            Impact factor:   1.150


  98 in total

1.  A role for skin gammadelta T cells in wound repair.

Authors:  Julie Jameson; Karen Ugarte; Nicole Chen; Pia Yachi; Elaine Fuchs; Richard Boismenu; Wendy L Havran
Journal:  Science       Date:  2002-04-26       Impact factor: 47.728

Review 2.  Starting at the beginning: new perspectives on the biology of mucosal T cells.

Authors:  Hilde Cheroutre
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

3.  High-dose IL-2 and IL-15 enhance the in vitro priming of naive CD4+ T cells for IFN-gamma but have differential effects on priming for IL-4.

Authors:  R A Seder
Journal:  J Immunol       Date:  1996-04-01       Impact factor: 5.422

4.  Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells: a role for IL-15 in attraction of T cells.

Authors:  H Jonuleit; K Wiedemann; G Müller; J Degwert; U Hoppe; J Knop; A H Enk
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

5.  Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.

Authors:  Diana I Albu; Agnes Jones-Trower; Amy M Woron; Kathleen Stellrecht; Christopher C Broder; Dennis W Metzger
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

6.  IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine.

Authors:  K Q Xin; K Hamajima; S Sasaki; T Tsuji; S Watabe; E Okada; K Okuda
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

Review 7.  IL-15 is a growth factor and an activator of CD8 memory T cells.

Authors:  Nan-Ping Weng; Kebin Liu; Marta Catalfamo; Yu Li; Pierre A Henkart
Journal:  Ann N Y Acad Sci       Date:  2002-12       Impact factor: 5.691

8.  Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts.

Authors:  R T Gazzinelli; S Hieny; T A Wynn; S Wolf; A Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

9.  Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells.

Authors:  Joyce T Tan; Bettina Ernst; William C Kieper; Eric LeRoy; Jonathan Sprent; Charles D Surh
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

10.  Durable cytotoxic immune responses against gp120 elicited by recombinant SV40 vectors encoding HIV-1 gp120 +/- IL-15.

Authors:  Hayley J McKee; Patricia Y T'sao; Maria Vera; Puri Fortes; David S Strayer
Journal:  Genet Vaccines Ther       Date:  2004-08-23
View more
  9 in total

1.  Treatment with Interleukin-7 Restores Host Defense against Pneumocystis in CD4+ T-Lymphocyte-Depleted Mice.

Authors:  S Ruan; D R Samuelson; B Assouline; M Morre; J E Shellito
Journal:  Infect Immun       Date:  2015-10-19       Impact factor: 3.441

2.  The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling.

Authors:  Youcai Deng; Jianhong Chu; Yulin Ren; Zhijin Fan; Xiaotian Ji; Bethany Mundy-Bosse; Shunzong Yuan; Tiffany Hughes; Jianying Zhang; Baljash Cheema; Andrew T Camardo; Yong Xia; Lai-Chu Wu; Li-Shu Wang; Xiaoming He; A Douglas Kinghorn; Xiaohui Li; Michael A Caligiuri; Jianhua Yu
Journal:  J Immunol       Date:  2014-08-13       Impact factor: 5.422

3.  Differential immune responses and microbiota profiles in children with autism spectrum disorders and co-morbid gastrointestinal symptoms.

Authors:  Destanie R Rose; Houa Yang; Gloria Serena; Craig Sturgeon; Bing Ma; Milo Careaga; Heather K Hughes; Kathy Angkustsiri; Melissa Rose; Irva Hertz-Picciotto; Judy Van de Water; Robin L Hansen; Jacques Ravel; Alessio Fasano; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2018-03-20       Impact factor: 7.217

4.  Pathogen-associated T follicular helper cell plasticity is critical in anti-viral immunity.

Authors:  Han Feng; Xiaohong Zhao; Jenny Xie; Xue Bai; Weiwei Fu; Hairong Chen; Hong Tang; Xiaohu Wang; Chen Dong
Journal:  Sci China Life Sci       Date:  2022-03-02       Impact factor: 10.372

5.  Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.

Authors:  Michael A Collier; Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Monica M Johnson; Andrew N Macintyre; Gregory D Sempowski; Eric M Bachelder; Jenny P-Y Ting; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2018-10-15       Impact factor: 4.939

6.  Vitamin A or E and a catechin synergize as vaccine adjuvant to enhance immune responses in mice by induction of early interleukin-15 but not interleukin-1β responses.

Authors:  Sapna Patel; Archana Akalkotkar; Joseph J Bivona; Ji-Young Lee; Young-Ki Park; Mingke Yu; Sara L Colpitts; Michael Vajdy
Journal:  Immunology       Date:  2016-06-22       Impact factor: 7.397

7.  Immunogenicity evaluation of a DNA vaccine expressing the hepatitis C virus non-structural protein 2 gene in C57BL/6 mice.

Authors:  Zahra Gorzin; Ali Akbar Gorzin; Alijan Tabarraei; Naser Behnampour; Shiva Irani; Amir Ghaemi
Journal:  Iran Biomed J       Date:  2014

Review 8.  Formulation technologies for oral vaccines.

Authors:  R R C New
Journal:  Clin Exp Immunol       Date:  2019-08-08       Impact factor: 4.330

9.  STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation.

Authors:  Bo-Dou Zhang; Jun-Jun Wu; Wen-Hao Li; Hong-Guo Hu; Lang Zhao; Pei-Yang He; Yu-Fen Zhao; Yan-Mei Li
Journal:  Nano Res       Date:  2022-04-18       Impact factor: 10.269
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.